Medical News Hubb
Advertisement
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
Medical News Hubb
No Result
View All Result
Home Medicines & Healthy Lifestyle

Deoxycytidine Kinase Inhibitor Designated Orphan Drug for Optic Neuritis

admin by admin
August 13, 2022
in Medicines & Healthy Lifestyle


The Food and Drug Administration (FDA) has granted Orphan Drug designation to TRE-515 for the treatment of demyelinating optic neuritis.

Optic neuritis (ON) is a rare autoimmune disease characterized by the inflammation of the optic nerve. The condition can lead to rapid loss of vision in one or both eyes. TRE-515 is a potential first-in-class, orally administered, small molecule inhibitor of deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway. 

“Inflammation damaging the protective myelin coating around the optic nerve causes ON, leading to pain and vision loss,” said Dr Peter Clark, member of the Trethera Scientific Advisory Board. “Targeting dCK with TRE-515 could limit this inflammation.”


Continue Reading

The FDA’s Orphan Drug designation is granted to medicines intended to treat or prevent rare diseases or disorders that affect fewer than 200,000 individuals.

“TRE-515 could potentially significantly benefit ON patients beyond the available therapeutic options, especially those taking long-term steroids,” said Trethera Scientific Advisory Board member Dr Larry Steinman.

Reference

Trethera announces FDA Orphan Drug designation granted to TRE-515 for the treatment of demyelinating optic neuritis. News release. Trethera Corporation. Accessed August 11, 2022. https://www.globenewswire.com/news-release/2022/08/09/2495188/0/en/Trethera-Announces-FDA-Orphan-Drug-Designation-Granted-to-TRE-515-for-the-Treatment-of-Demyelinating-Optic-Neuritis.html

This article originally appeared on MPR

Topics:

Immune Disorders
Ophthalmic Disorders



Source link

Previous Post

CDC Introduces Streamlined Guidelines For Better COVID-19 Protection, Understanding

Next Post

Health Bulletin 12/August/2022

Next Post

Health Bulletin 12/August/2022

Recommended

Former FDA commissioner on loosened restrictions on abortion pills

January 7, 2023

Keytruda Approved as Adjuvant Treatment for Stage IB, II, or IIIA NSCLC

January 30, 2023

Don't miss it

Pharmaceutical

AbbVie to lift $2B deal cap as Humira rivals appear

February 6, 2023
Medicines & Healthy Lifestyle

Trial Investigating Pembrolizumab for Hormone-Sensitive Prostate Cancer Discontinued

February 6, 2023
Medicines & Healthy Lifestyle

Low Sex Drive Can Be Treated By Hormone Injections, Study Shows

February 6, 2023
News

USTR Seeks Public Comment on Restoring Tariffs on Chinese Medical Products

February 6, 2023
Pharmaceutical

Health Bulletin 6/ February/ 2023

February 6, 2023
Pharmaceutical

FDA: Base blood donation policy on science, not stigma

February 5, 2023

© 2022 Medical News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

Newsletter Sign Up

No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

© 2022 Medical News Hubb All rights reserved.